...
首页> 外文期刊>Antimicrobial agents and chemotherapy. >Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
【24h】

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.

机译:非核苷类逆转录酶抑制剂在体外抗性选择过程中非亚型B HIV-1的不同突变途径。

获取原文
获取原文并翻译 | 示例

摘要

Studies were conducted to investigate mutation pathways among subtypes A, B, and C of human immunodeficiency virus type 1 (HIV-1) during resistance selection with nonnucleoside reverse transcriptase inhibitors (NNRTIs) in cell culture under low-multiplicity of infection (MOI) conditions. The results showed that distinct pathways were selected by different virus subtypes under increasing selective pressure of NNRTIs. F227C and Y181C were the major mutations selected by MK-4965 in subtype A and C viruses during resistance selection. With efavirenz (EFV), F227C and V106M were the major mutations responsible for viral breakthrough in subtype A viruses, whereas a single pathway (G190A/V106M) accounted for mutation development in subtype C viruses. Y181C was the dominant mutation in the resistance selection with etravirine (ETV) in subtype A, and E138K/H221Y were the mutations detected in the breakthrough viruses from subtype C viruses with ETV. In subtype B viruses, on the other hand, known NNRTI-associated mutations (e.g., Y181C, P236L, L100I, V179D, and K103N) were selected by the NNRTIs. The susceptibility of the subtype A and B mutant viruses to NNRTIs was determined in order to gain insight into the potential mechanisms of mutation development. Collectively, these results suggest that minor differences may exist in conformation of the residues within the NNRTI binding pocket (NNRTIBP) of reverse transcriptase (RT) among the three subtypes of viruses. Thus, the interactions between NNRTIs and the residues in the NNRTIBPs of different subtypes may not be identical, leading to distinct mutation pathways during resistance selection in cell culture.
机译:进行研究以调查在低多重感染(MOI)条件下在细胞培养中使用非核苷类逆转录酶抑制剂(NNRTIs)进行抗性选择期间人类免疫缺陷病毒1型(HIV-1)的A,B和C亚型之间的突变途径。结果表明,在增加的NNRTIs选择压力下,不同的病毒亚型选择了不同的途径。在抗性选择过程中,F227C和Y181C是MK-4965在A型和C型亚型病毒中选择的主要突变。对于依法韦仑(EFV),F227C和V106M是导致A型亚型病毒突破病毒的主要突变,而单一途径(G190A / V106M)则说明了C型亚型病毒的突变发展。 Y181C是A亚型对Etravirine(ETV)的抗性选择中的主要突变,E138K / H221Y是在ETV C型亚型病毒的突破性病毒中检测到的突变。另一方面,在B型亚型病毒中,NNRTI选择了已知的与NNRTI相关的突变(例如Y181C,P236L,L100I,V179D和K103N)。确定A和B型亚型突变病毒对NNRTIs的敏感性,以便深入了解突变发展的潜在机制。总体而言,这些结果表明,三种亚型的病毒在逆转录酶(RT)的NNRTI结合袋(NNRTIBP)内的残基构象可能存在细微差异。因此,NNRTIs和不同亚型的NNRTIBPs中的残基之间的相互作用可能不相同,从而在细胞培养的抗性选择过程中导致截然不同的突变途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号